Binks SNM., Veldsman M., Handel AE., Jacob S., Maddison P., Coebergh J., Michael S., Ramanathan S., Easton A., Nissen MS., Leite MI., Okai D., Blaabjerg M., Husain M., Irani SR.

AbstractPatient‐reported quality‐of‐life (QoL) and carer impacts are not reported after leucine‐rich glioma‐inactivated 1‐antibody encephalitis (LGI1‐Ab‐E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five‐item battery explained most variance in QoL. Wide‐ranging impacts post‐LGI1‐Ab‐E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.

Fatigue predicts quality of life after leucine‐rich glioma‐inactivated 1‐antibody encephalitis

Binks SNM., Veldsman M., Handel AE., Jacob S., Maddison P., Coebergh J., Michael S., Ramanathan S., Easton A., Nissen MS., Leite MI., Okai D., Blaabjerg M., Husain M., Irani SR.

DOI

Type

Journal

Publisher

Publication Date